Short Interest in SOPHiA GENETICS SA (NASDAQ:SOPH) Expands By 155.9%

SOPHiA GENETICS SA (NASDAQ:SOPH) was the target of a significant growth in short interest during the month of May. As of May 31st, there was short interest totalling 54,000 shares, a growth of 155.9% from the May 15th total of 21,100 shares. Currently, 0.1% of the shares of the stock are short sold. Based on an average daily volume of 98,900 shares, the days-to-cover ratio is presently 0.5 days.

Wall Street Analyst Weigh In

A number of research analysts have commented on the company. BTIG Research increased their price objective on SOPHiA GENETICS from $7.00 to $8.00 and gave the company a “buy” rating in a research report on Wednesday, March 6th. Royal Bank of Canada reiterated an “outperform” rating and issued a $8.00 price target on shares of SOPHiA GENETICS in a report on Wednesday, March 6th.

Hedge Funds Weigh In On SOPHiA GENETICS

Hedge funds have recently added to or reduced their stakes in the stock. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of SOPHiA GENETICS by 90.0% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,834 shares of the company’s stock valued at $65,000 after acquiring an additional 6,552 shares during the last quarter. Legato Capital Management LLC bought a new stake in SOPHiA GENETICS in the fourth quarter valued at approximately $235,000. Federated Hermes Inc. raised its holdings in SOPHiA GENETICS by 100.0% in the third quarter. Federated Hermes Inc. now owns 160,000 shares of the company’s stock worth $408,000 after purchasing an additional 80,000 shares during the period. Essex Investment Management Co. LLC acquired a new stake in SOPHiA GENETICS in the fourth quarter worth $584,000. Finally, Moloney Securities Asset Management LLC boosted its position in shares of SOPHiA GENETICS by 111.4% during the first quarter. Moloney Securities Asset Management LLC now owns 178,000 shares of the company’s stock worth $878,000 after purchasing an additional 93,800 shares in the last quarter. Institutional investors and hedge funds own 31.59% of the company’s stock.

SOPHiA GENETICS Stock Down 0.2 %

NASDAQ SOPH traded down $0.01 during trading hours on Friday, hitting $4.83. The company’s stock had a trading volume of 44,760 shares, compared to its average volume of 147,213. SOPHiA GENETICS has a twelve month low of $2.13 and a twelve month high of $7.37. The firm has a market capitalization of $315.79 million, a P/E ratio of -4.31 and a beta of 1.09. The stock has a fifty day moving average of $4.90 and a 200 day moving average of $4.78.

SOPHiA GENETICS (NASDAQ:SOPH) last posted its quarterly earnings results on Tuesday, May 7th. The company reported ($0.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.04. SOPHiA GENETICS had a negative return on equity of 47.56% and a negative net margin of 113.71%. The company had revenue of $15.78 million for the quarter, compared to the consensus estimate of $16.80 million. On average, analysts predict that SOPHiA GENETICS will post -1.04 earnings per share for the current year.

About SOPHiA GENETICS

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.